Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 3/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30922407 | 0.86 | ALDH1A1 (0.39) | CYP4F2CYP4A11LMNAALDH1A1POLB | |
| SCHEMBL29344298 | 0.86 | CYP4F2 (0.41) | CYP4F2CYP4A11LMNAALDH1A1POLB | |
| SCHEMBL26124827 | 0.84 | CYP4F2 (0.41) | CYP4F2CYP4A11LMNAALDH1A1POLB | |
| SCHEMBL29474190 | 0.83 | CYP4F2 (0.42) | CYP4F2CYP4A11LMNAALDH1A1POLB | |
| SCHEMBL28954100 | 0.83 | CYP4F2 (0.42) | CYP4F2CYP4A11LMNAALDH1A1POLB | |
| SCHEMBL24274351 | 0.83 | LMNA (0.43) | CYP4F2CYP4A11LMNAALDH1A1POLB | |
| SCHEMBL29593100 | 0.83 | CYP4F2 (0.45) | CYP4F2CYP4A11LMNAALDH1A1POLB | |
| SCHEMBL21379219 | 0.83 | CYP4F2 (0.45) | CYP4F2CYP4A11LMNAALDH1A1POLB | |
| SCHEMBL21195912 | 0.83 | CYP4F2 (0.42) | CYP4F2CYP4A11LMNAALDH1A1POLB | |
| SCHEMBL29385882 | 0.83 | CYP4F2 (0.42) | CYP4F2CYP4A11LMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219956-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219956-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCG2, NQO2 | CYP4F2 606/4885CYP4A11 836/4885LMNA 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.